Relatlimab,Nivolumab
BMS
['melanoma']
live at #asco23: explore the next phase of the #immunotherapy revolution in #melanoma with drs. , kari kendra, &amp; , as they discuss and dissect the latest data for #pd1 &amp; #lag3 inhibitors. join the livestream here or at : 
Improving the knowledge, skills, and strategies that support clinical performance and patient outcomes through the provision of live and on-demand CE